Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939217 | 0.86 | JUN (0.44) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL937296 | 0.83 | PANK3 (0.48) | LMNASCDPANK3 | |
| SCHEMBL936146 | 0.81 | JUN (0.47) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL937874 | 0.80 | JUN (0.46) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL8310937 | 0.78 | NPC1 (0.47) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL936283 | 0.78 | PANK3 (0.41) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL8310344 | 0.78 | JUN (0.48) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL20460466 | 0.77 | JUN (0.48) | JUNNFKB1NFKB2RELAMAOB | |
| SCHEMBL8308548 | 0.76 | HPGD (0.54) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL20152022 | 0.75 | JUN (0.48) | JUNNFKB1NFKB2RELAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | JUN 4366/4885NFKB1 2447/4885NFKB2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.